Last edition
News about "Stempeucel therapy"
Medinet Japan partners with India's Stempeutics for Stempeucel cell therapy to treat CLTI
Medinet Co., Ltd, a Tokyo-listed regenerative medicine and CDMO company, has signed an option licence agreement with India-based Stempeutics Research for the development and commercialisation of its Stempeucel therapy in Japan, targeting Chronic Limb Threatening Ischaemia (CLTI).
Stempeucel Therapy | 29/10/2025 | By Darshana | 161
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members